We're talking about the same trial and the same results - just different ways of saying it.
1 of 3 patients experienced a CR - 33% (the response just so happened to be AML)
1 of 1 AML patient experienced a CR - 100%
The trial is a multi-indication trial so I think it's disingenuous to use the latter. Whatever way you cut it, positive to see any CR in a P1b trial and atrocious by management that they announced it during a suspension and conducted a raise that benefited insiders and shafted holders.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |